AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

683.947

+0.7470.11%

Number of Gainers:19

Number of Losers:5

Number of Flat:21

PE:- -

High:691.975

Open:684.744

Low:682.775

Close:683.200

Volume:36.26M

Turnover:94.15M

Market Cap:102.25B

Float Cap:98.92B

Loading ...

Proteomics Says Racehorse Performance Data Confirms Potential of Unit's Stress Testing Technology; Shares Jump 5%

MT Newswires Live

Monash IVF Rejects Proposal To Acquire Co

BRIEF-Patrys Seeks Trading Halt

BUZZ-Australia's Monash IVF soars on rejecting takeover bid

Patrys Ltd-Trading Halt

THOMSON REUTERS

Patrys Ltd - Requests Trading Halt Pending Acquisition Announcement

THOMSON REUTERS

Monash IVF Group Ltd-Monash IVF Rejects Nbio Proposal to Acquire Mvf

THOMSON REUTERS

Monash IVF Group Ltd - Indicative Cash Price Offered to Shareholders Under Proposal Is a$0.80 per Share

THOMSON REUTERS

Immuron Limited Announces Director Interest Disclosure Availability

How a Seasoned CFO Appointment Could Shape Mesoblast's (ASX:MSB) Commercial Transformation

Simply Wall St.

Mayne Pharma Says Scheme of Arrangement for Proposed Takeover by Cosette 'Unlikely to Proceed'

MT Newswires Live

Mayne Pharma Group Ltd - Consulting on Alternatives After Firb Condition Failure

THOMSON REUTERS

Mayne Pharma Group Ltd-Update on Firb Condition and Scheme

THOMSON REUTERS

Mayne Pharma Group Ltd - Second Court Hearing Vacated

THOMSON REUTERS

Australia Blocks Cosette's Proposed Mayne Pharma Acquisition on National Interest Grounds

MT Newswires Live

Mesoblast to Conduct Pivotal Ryoncil Trial in Adults With Severe Acute Graft Versus Host Disease

MT Newswires Live

Mayne Pharma Requests Trading Halt Ahead of Cosette Deal Update

MT Newswires Live

Australia Treasurer: to Block Cosette Pharmaceuticals Bid to Buy Mayne Pharma Group on National Interest Grounds

THOMSON REUTERS

CSL (ASX:CSL) Valuation in Focus After $1.5 Billion US Expansion Plan Announced

Simply Wall St.

BRIEF-Mayne Pharma Seeks Trading Halt

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":683.94653,"timestamp":1764305999920,"preClose":683.1998,"halted":0,"volume":36263776,"delay":0,"changeRate":0.001093,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0.746704,"latestTime":"11-28 16:00:00 AEDT","open":684.7437,"high":691.9752,"low":682.7754,"amount":94147851,"amplitude":0.013466,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1764543600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1764284400000,1764306000000]],"turnoverRate":0.001393,"increases":18,"decrements":6,"flats":20,"marketCap":102252356698,"floatMarketCap":98921583918.9375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":691.9752,"amplitude":0.013466,"preClose":683.1998,"low":682.7754,"latestPrice":683.94653,"volume":36263776,"delay":0,"open":684.7437,"prevYearClose":936.801,"prevWeekClose":683.947,"prevMonthClose":683.947,"prevQuarterClose":712.826,"fiveDayClose":654.211,"twentyDayClose":662.953,"sixtyDayClose":747.652,"secType":"PLATE","market":"AU","turnoverRate":0.001393,"marketCap":102252356698,"floatMarketCap":98921583918.9375,"timestamp":1764305999920,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":19,"down":5,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2585437143","title":"Proteomics Says Racehorse Performance Data Confirms Potential of Unit's Stress Testing Technology; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437143","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437143?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:47","pubTimestamp":1763956054,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  said performance data on Australian thoroughbred racehorses supports the potential of its OxiDx unit's oxidative stress testing technology in providing insight into the physiological readiness of racehorses, according to a Monday filing with the Australian bourse.New findings gathered using the OxiDx test showed that thoroughbred horses racing without oxidative stress were 76% more likely to place and 49% more likely to win than horses with oxidative stress, the filing said.Horses racing without oxidative stress increased the likelihood of winning or placing in the top three, the filing added.Shares of the company rose 5% in recent Monday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XJO.AU","BK7048","BK7508","XAO.AU","PIQ.AU"],"gpt_icon":0},{"id":"2585314924","title":"Monash IVF Rejects Proposal To Acquire Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2585314924","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585314924?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:56","pubTimestamp":1763949389,"startTime":"0","endTime":"0","summary":"Nov 24 (Reuters) - Monash IVF Group Ltd ::*MONASH IVF REJECTS NBIO PROPOSAL TO ACQUIRE MVF*INDICATIVE CASH PRICE OFFERED TO SHAREHOLDERS UNDER PROPOSAL IS A$0.80 PER SHARE*PROPOSAL FROM A CONSORTIUM C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nRSD7BvbHm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7113","BK7508","MVF.AU"],"gpt_icon":0},{"id":"2585431939","title":"BRIEF-Patrys Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2585431939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585431939?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:46","pubTimestamp":1763948770,"startTime":"0","endTime":"0","summary":"BRIEF-Patrys Seeks Trading HaltNov 24 (Reuters) - Patrys Ltd PAB.AX:TRADING HALTREQUESTS TRADING HALT PENDING ACQUISITION ANNOUNCEMENTFurther company coverage: PAB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUEB8GXY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2585435549","title":"BUZZ-Australia's Monash IVF soars on rejecting takeover bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435549","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585435549?lang=en_us&edition=fundamental","pubTime":"2025-11-24 07:50","pubTimestamp":1763941853,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Monash IVF soars on rejecting takeover bid** Shares of Monash IVF Group MVF.AX rose as much as 36.1% to A$0.83, their largest pct jump to date** Stock hits highest level since August 21** IVF clinics operator rejects conditional and non-binding indicative proposal from a consortium including Genesis Capital Investment Management** Offer price of A$0.8 represents 31.1% premium on last close** Co says current proposal is at a \"substantial discount to comparable IVF transactions in the Australian market\"** Stock down 35.4% YTD, including the day's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251123:nL4N3WZ05Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MVF.AU","BK7508","BK7113"],"gpt_icon":0},{"id":"2585619438","title":"Patrys Ltd-Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2585619438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585619438?lang=en_us&edition=fundamental","pubTime":"2025-11-24 06:04","pubTimestamp":1763935449,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251123:nTUEB8GXY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2585143861","title":"Patrys Ltd - Requests Trading Halt Pending Acquisition Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2585143861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585143861?lang=en_us&edition=fundamental","pubTime":"2025-11-24 06:04","pubTimestamp":1763935449,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251123:nTUEB8GXY0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2585367438","title":"Monash IVF Group Ltd-Monash IVF Rejects Nbio Proposal to Acquire Mvf","url":"https://stock-news.laohu8.com/highlight/detail?id=2585367438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585367438?lang=en_us&edition=fundamental","pubTime":"2025-11-24 05:46","pubTimestamp":1763934380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251123:nTUE7VGKC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MVF.AU","BK7113"],"gpt_icon":0},{"id":"2585043836","title":"Monash IVF Group Ltd - Indicative Cash Price Offered to Shareholders Under Proposal Is a$0.80 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2585043836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585043836?lang=en_us&edition=fundamental","pubTime":"2025-11-24 05:46","pubTimestamp":1763934380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251123:nTUE7VGKC3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7113","MVF.AU","BK7508"],"gpt_icon":0},{"id":"2585259921","title":"Immuron Limited Announces Director Interest Disclosure Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2585259921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585259921?lang=en_us&edition=fundamental","pubTime":"2025-11-22 04:51","pubTimestamp":1763758275,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL5ySGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immuron Limited Announces Director Interest Disclosure Availability","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2585417117","title":"How a Seasoned CFO Appointment Could Shape Mesoblast's (ASX:MSB) Commercial Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585417117","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585417117?lang=en_us&edition=fundamental","pubTime":"2025-11-21 16:18","pubTimestamp":1763713089,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently announced the appointment of James M. O’Brien as its new US-based Chief Financial Officer, drawing on his extensive financial leadership across global life sciences, biotechnology, and pharmaceutical companies.\nO’Brien’s expertise in orchestrating large-scale corporate transactions and public offerings brings significant operational and financial acumen to Mesoblast's transition into a fully integrated commercial organization.\nWe’ll now explore how the addition of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/how-a-seasoned-cfo-appointment-could-shape-mesoblasts-asxmsb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/how-a-seasoned-cfo-appointment-could-shape-mesoblasts-asxmsb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","MSB","MSB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2585191975","title":"Mayne Pharma Says Scheme of Arrangement for Proposed Takeover by Cosette 'Unlikely to Proceed'","url":"https://stock-news.laohu8.com/highlight/detail?id=2585191975","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585191975?lang=en_us&edition=fundamental","pubTime":"2025-11-21 14:15","pubTimestamp":1763705730,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  said that the scheme of arrangement for the proposed acquisition of the firm by Cosette Pharmaceuticals is \"unlikely to proceed\" because the Foreign Investment Review Board condition precedent will not be satisfied, according to a Friday Australian bourse filing.The second court hearing scheduled for Nov. 23 was vacated.It received a notice from Cosette under the scheme implementation deed, asking the parties to \"consult in good faith\" under the deed's clauses in relation to available alternatives. Mayne said it was assessing its options and next steps.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2585992721","title":"Mayne Pharma Group Ltd - Consulting on Alternatives After Firb Condition Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2585992721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585992721?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:51","pubTimestamp":1763704271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUEB7TDF1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2585205199","title":"Mayne Pharma Group Ltd-Update on Firb Condition and Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2585205199","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585205199?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:51","pubTimestamp":1763704271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUEB7TDF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2585199209","title":"Mayne Pharma Group Ltd - Second Court Hearing Vacated","url":"https://stock-news.laohu8.com/highlight/detail?id=2585199209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585199209?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:51","pubTimestamp":1763704271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUEB7TDF1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2585519648","title":"Australia Blocks Cosette's Proposed Mayne Pharma Acquisition on National Interest Grounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2585519648","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585519648?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:03","pubTimestamp":1763701420,"startTime":"0","endTime":"0","summary":"Australian Treasurer Jim Chalmers decided to block Cosette Pharmaceuticals' proposed acquisition of Mayne Pharma Group  on national interest grounds, following the Foreign Investment Review Board's recommendation, Chalmers said in a Friday statement.The decision was made to \"protect the security of our critical medical supply chains,\"  he said.The treasurer said he also received advice from the Department of Health and Aged Care, the Therapeutic Goods Administration, and the South Australian government.Mayne Pharma and Cosette Pharmaceuticals did not immediately respond to MT Newswires' request for comment.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7096","MYX.AU","NHLD","XJO.AU","XKO.AU","BK7508"],"gpt_icon":0},{"id":"2585457162","title":"Mesoblast to Conduct Pivotal Ryoncil Trial in Adults With Severe Acute Graft Versus Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2585457162","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585457162?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:36","pubTimestamp":1763688983,"startTime":"0","endTime":"0","summary":"Mesoblast  will collaborate with the Blood and Marrow Transplant Clinical Trials Network on a pivotal trial of Ryoncil as part of a first-line regimen in adults with severe acute graft versus host disease refractory to corticosteroids, according to a Friday Australian bourse filing.The patients will be randomized in the trial as early as possible after corticosteroid refractoriness to receive ruxolitinib alone or combined with Ryoncil to give them the best chance of survival.The trial protocol will be provided to the US Food and Drug Administration to initiate enrollment in the first quarter of 2026. Mesoblast recently met with the US FDA to discuss the most appropriate patient population and timing of treatment in a pivotal trial of Ryoncil for adults with severe acute graft versus host disease.Ryoncil is already approved by the FDA in children and adolescents.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HST","MESO","BK4218","BK7508","BK4139","BK4181","BK7501","BK4585","BK4588","BK7067","MSB.AU"],"gpt_icon":0},{"id":"2585641361","title":"Mayne Pharma Requests Trading Halt Ahead of Cosette Deal Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2585641361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585641361?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:09","pubTimestamp":1763687344,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  requested an immediate trading halt pending an update on its proposed acquisition by Cosette via a scheme of arrangement, according to a Friday Australian bourse filing.The trading halt will remain in effect until either the disclosure is released or normal trading resumes on Nov. 25, whichever occurs first, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XAO.AU","BK7096","XKO.AU","XJO.AU","MYX.AU"],"gpt_icon":0},{"id":"2585166100","title":"Australia Treasurer:  to Block Cosette Pharmaceuticals Bid to Buy Mayne Pharma Group on National Interest Grounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2585166100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585166100?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:45","pubTimestamp":1763682359,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nP8N3MH03P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2585193422","title":"CSL (ASX:CSL) Valuation in Focus After $1.5 Billion US Expansion Plan Announced","url":"https://stock-news.laohu8.com/highlight/detail?id=2585193422","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585193422?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:37","pubTimestamp":1763681861,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has announced a $1.5 billion investment over the next five years to expand its United States operations. This move is intended to boost the clinical supply of immunoglobulin and reinforce its domestic manufacturing base.\nSee our latest analysis for CSL.\nDespite CSL’s continued push to expand its U.S. presence and deepen its manufacturing capabilities, the shares have endured a challenging run, with a 1-year total shareholder return of -33.6%. Recent news about the $1.5 billion...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-valuation-in-focus-after-15-billion-us-expansion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-valuation-in-focus-after-15-billion-us-expansion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4086","CSL","BK7508","BK7501","SG9999004303.SGD","LU0728928796.USD","SGXZ23171101.USD","CSL.AU","LU1169590202.USD","LU1169589451.USD","BK7511"],"gpt_icon":0},{"id":"2585861166","title":"BRIEF-Mayne Pharma Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2585861166","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585861166?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:28","pubTimestamp":1763681290,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Seeks Trading HaltNov 21 (Reuters) - Mayne Pharma MYX.AX:TRADING HALTSEEKS TRADING HALT PENDING ANNOUNCEMENT ON  PROPOSED ACQUISITION BY COSETTE BY WAY OF A SCHEME OF ARRANGEMENTFurther company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUEB7WS3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":129,"code":"91000000","status":"200"}]}}